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Introduction
APC mutations activate aberrant β -catenin signaling to drive colorectal tumorigenesis (1) . However, colorectal cancer (CRC) progression, especially invasiveness, requires additional molecular mechanisms (2, 3) . The presence of CRC invasion in colorectal polyps profoundly worsen patients' outcomes (4) . Identification of critical invasiveness-regulating mechanisms can therefore open opportunities for molecular targeting.
The ligand-activated nuclear receptor peroxisome proliferator-activated receptor-δ/β (PPARD) has pleiotropic effects on cell homeostasis (5) . PPARD is upregulated in human colorectal polyps and CRC (6) (7) (8) (9) and has been identified as a downstream target of the β -catenin/TCF4 complex in CRC cell lines (6) . However, this proposed mechanistic link between β -catenin and PPARD has been questioned on the basis of in vitro and in vivo data (10) . More importantly, germline PPARD knockout (KO) in Apc min mice produced conflicting results, both increasing (11) and decreasing (12) intestinal tumorigenesis.
Nevertheless, other studies suggested that PPARD increases β -catenin activation in human cholangiocarcinoma cells (13) and in normal osteocytes (14) . Recently, a high-fat diet was reported to increase β -catenin activation via PPARD in progenitor intestinal cells of Apc min mice (15) . Clearly, the role of PPARD in colorectal tumorigenesis, especially in relation to APC and aberrant β -catenin activation, remains highly controversial (16, 17) . Filling this knowledge gap is important because PPARD is a druggable protein for which agonists and antagonists have been developed. Although the clinical testing and pharmaceutical development of PPARD agonists by large pharmaceutical companies to treat noncancerous conditions (e.g., obesity) has been halted in many instances, these agents (e.g., cardarine [GW501516]) are still sold on the internet black market to athletes wishing to enhance muscle endurance. Therefore, preclinical data clarifying the role of PPARD in CRC are urgently needed to educate the public about the potential risk of promoting colorectal tumorigenesis with PPARD agonists.
We therefore tested PPARD's effects on aberrant β -catenin activation-driven colon tumorigenesis using murine genetic models of human CRC with representative APC mutations (18) with concomitant PPARD overexpression in intestinal epithelial cells (IECs). Our data showed that PPARD strongly enhanced aberrant β -catenin activation and more importantly it robustly activated CRC proinvasive pathways to promote CRC progression and invasion.
Results

PPARD activates β -catenin in IECs
Aberrant β -catenin activation via APC mutations upregulates PPARD (6) . We therefore tested whether PPARD upregulation is sufficient to increase β -catenin activation independently of APC mutations by using PD mice with wild-type (WT) APC ( Supplementary Fig. 1a ). PPARD overexpression markedly increased active β -catenin protein levels in IECs (Fig.1a) . The PPARD agonist GW501516 augmented the effects of PPARD in PD mice compared to their WT littermates ( Supplementary Fig. 1b ). PPARD overexpression also significantly increased mRNA levels of Axin2 and cyclinD1, downstream targets of active β -catenin, in IECs (Fig. 1b) . Aberrant β -catenin activation expands the dedifferentiated intestinal stem cell population to promote colorectal tumorigenesis (19) . Intestinal organoid formation, especially in its primitive spheroid form, was markedly higher when IECs were derived from PD mice than from their WT littermates (Fig. 1c) .
We further examined whether PPARD activates 1i ), whereas the PPARD antagonist GSK3787 decreased c-Myc mRNA expression even in GW0742-treated cells (Fig. 1i) . We confirmed PPARD activation by GW0742 and inhibition by GSK3787 in HCT-116 cells by measuring expression of angiopoietin-like 4 (AngPTL4) ( Supplementary Fig. 1c ), a wellestablished PPARD target gene.
PPARD enhances aberrant β -catenin signaling in IECs with APC mutations
Apc min mice mainly develop small intestinal adenomas, unlike humans, in whom intestinal tumorigenesis is essentially colorectal and can progress to invasive cancer. In contrast to Apc min mice, targeting the APC mutation into the intestine via CDX2 promoter-driven Cre recombinase expression to produce a codon 580 frame-shift mutation, as in Apc (Fig. 2f,g ).
PPARD activates β -catenin via BMP7/TAK1 signaling in IECs
To determine the molecular mechanisms by which PPARD enhanced β -catenin activation, we used comparative transcriptome profile analyses (RNA sequencing) of HCT-116-WT and KO1 (HCT-116 PPARD KO) cells (9) . These analyses revealed that bone morphogenetic protein 7 (BMP7) mRNA expression was 11-fold higher in WT cells than in KO1 cells ( Supplementary Fig. 2a ). Independent quantitative real-time polymerase chain reaction (qRT-PCR) measurements confirmed this finding (Fig.   3a ). BMP7 phosphorylates mitogen-activated protein kinase kinase kinase 7 (TAK1) to activate β -catenin (20) . BMP7 and phosphorylated TAK1 (p-TAK1) protein levels were lower in HCT-116 KO1 cells than in WT cells (Fig. 3b) . PPARD overexpression by lentivirus transduction in SW480 colon cancer cells with low BMP7 expression significantly increased expression of BMP7 mRNA (Fig. 3c ), BMP7
protein, p-TAK1, phosphorylated P38 (p-p38), and active β -catenin protein (Fig. 3d) . We next examined whether PPARD transcriptionally regulates BMP7 expression via binding to a potential PPARD binding site (pPDBS) in the BMP7 promoter (Fig. 3e ). An in silico search using Genomatix MatInspector online software identified a pPDBS in the BMP7 promoter region near the transcription start site (Fig. 3e ).
PPARD overexpression in SW480 cells significantly increased PPARD binding (measured by a chromatin immunoprecipitation/quantitative PCR assay) to this pPDBS in the BMP7 promoter (Fig. 3f ).
To further clarify PPARD's mechanistic significance to the BMP7-TAK1-β-catenin signaling pathway, we employed a TAK1-specific inhibitor, 5z-7, to treat SW480 cells in which this signaling pathway was activated by PPARD overexpression. 5z-7 inhibited the increase in active β -catenin protein levels induced by PPARD overexpression in SW480 cells (Fig. 3g) , thus confirming TAK1's mechanistic contribution to PPARD activation of β -catenin. In SW620 cells with intrinsic activation of BMP7-TAK1-β-catenin signaling,(20) the specific PPARD inhibitor GSK3787 reduced active β -catenin protein levels to those achieved with 5z-7 ( Fig. 3h) . In vivo, PPARD increased BMP7 mRNA levels ( Fig.   3i ) and BMP7, p-TAK1, and p38 protein levels ( Similarly, BMP7 mRNA levels ( Fig. 3m ) and BMP7, p-TAK1, p38, and p-p38 protein levels were significantly higher in IECs of Apc (Fig. 3n) .
PPARD accelerates APC mutation-driven intestinal tumorigenesis
Germline KO of PPARD in Apc min mouse models produced contradictory results (11, 12) . PPARD is, however, overexpressed in IECs of human CRC (6) (7) (8) (9) . We therefore sought to test the effects of PPARD overexpression in IECs of APC-mutant mice. Breeding Apc min and PD mice generated Apc min -PD mice ( Supplementary Fig. 3a) , which rapidly developed a large intestinal tumor burden and required euthanasia. Apc min -PD mice had significantly more and larger intestinal tumors than did their littermate Apc min mice (Fig. 4a,b) . We also tested the effects of PPARD overexpression in IECs on tumorigenesis in Apc Δ 580 mice, which better simulate human APC mutation-driven CRC tumorigenesis than do Apc min mice (18) . Apc (Fig. 4c,d and Supplementary Fig. 3b,c) . In addition, Apc We next tested the effects of the PPARD agonist GW501516 in Apc Δ 580 mice using a diet containing 50 mg/kg GW501516. GW501516 diet produced significantly more and larger intestinal tumors than did the control diet (Fig. 4f,g and Supplementary Fig. 3f,g ). The median survival of GW50106-treated Apc We also examined the effects of PPARD overexpression on adult-onset APC mutation using tamoxifen-inducible Apc 
PPARD promotes CRC invasiveness
The transformation to invasive CRC occurs in large adenomas (3) . PPARD overexpression in IECs significantly increased the number of large tumors in Apc min -PD, Apc were significantly higher in the CRC invasive fronts than in their paired tumor centers or adenomas (Fig. 5d,e) .
PPARD regulates PDGFRβ expression in CRC tumorigenesis
We screened for downstream target genes of PPARD that promoted intestinal tumorigenesis using (Fig. 6g,h ). In data from
The Cancer Genome Atlas (TCGA) provisional colorectal cancer database, PDGFRβ and PPARD mRNA levels were significantly correlated, with a tendency towards co-occurrence (log odds ratio = 2.348; P < 0.001) (Fig. 6i) . On examining PDGFRβ's mechanistic significance to PPARD's promotion of CRC invasion, we found that PPARD overexpression in CT26 mouse CRC cells significantly increased cell migration and that DMPQ (a specific PDGFRβ inhibitor (22) ) reduced cell migration promoted by PPARD (Fig. 6j) .
PPARD activates AKT-rpS6 signaling to promote intestinal tumorigenesis
Independent experiments confirmed that PPARD upregulated AKT1 protein expression in PD (Fig. 7a) and Apc Δ 580 -PD mice (Fig. 7b) . In contrast, AKT2 expression remained unchanged (Fig. 7a,b and Supplementary Fig. 4a,b) . PPARD also increased AKT1 phosphorylation and activation as measured by phosphorylation of downstream target proteins rpS6 and glycogen synthase kinase 3β (GSK3β) (Fig. 7a,b and Supplementary Fig. 4c,d ). Furthermore, we found that PPARD overexpression upregulated AKT1 mRNA levels in IECs of PD and Apc Δ 580 -PD mice (Fig. 7c,d ). When we integrated data from the TCGA colorectal cancer databases to determine the relevance of these results to human CRC, we found significant correlation between PPARD and AKT1 mRNA expression levels (Fig. 7e) .
Furthermore, PPARD overexpression via lentivirus transduction increased AKT1 mRNA and protein expression and phosphorylation (Fig. 7f,g ). PPARD KO HCT-116 cells (KO1) had lower AKT1 and prpS6 expression levels than did parental HCT-116 WT cells ( Supplementary Fig. 4e ). PPARD downregulation using 2 independent PPARD small interfering RNAs (siRNAs) in SW480 cells reduced AKT1 mRNA and protein levels and phosphorylation (Fig. 7h,i) . Finally, we evaluated whether PPARD as a transcriptional factor acted directly by binding to the AKT1 promoter by identifying a pPDBS in an in silico search (Fig. 7j) . PPARD overexpression in SW480 cells via PPARD lentivirus transduction significantly increased PPARD binding activity at the identified pPDBS site of the AKT1 promoter (Fig.   7k ).
We examined the biological significance of AKT upregulation by PPARD for CRC invasiveness by conducting a cell migration assay using an AKT-selective inhibitor, MK2206. PPARD overexpression in HCT-116 cells significantly increased the number of migrated cells, and MK2206 attenuated these effects (Fig. 7l,m) .
PPARD increases protein synthesis to promote intestinal tumorigenesis
In further independent reverse phase protein array experiments, we confirmed that CDK1 expression was significantly higher in PD and Apc Δ 580 -PD mice than in their control littermates at both the mRNA (Fig. 8a,b) and protein (Fig. 8c,d (Fig. 8e,f) .
DISCUSSION
We found that PPARD potentiated We found that PPARD activates β -catenin via upregulating BMP7 to phosphorylate TAK1. Our data demonstrate for the first time that PPARD transcriptionally upregulates BMP7 expression, which subsequently activates TAK1/β-catenin signaling. Previously, the BMP7/TAK1/β-catenin signaling pathway was reported to be selectively active in APC-and KRAS-mutant colon cancer cells and to contribute to therapeutic resistance (20) . We showed that a PPARD inhibitor, GSK3787, suppressed . These data clearly demonstrate that PPARD regulates this therapeutic resistance pathway.
In addition, we determined that PPARD transcriptionally upregulates BMP7 to activate TAK1. Prior reports have been inconsistent regarding PPARD's relation to TAK1. PPARD agonists have been reported to inhibit TAK1 phosphorylation in rodent renal tubular (25) and peritoneal mesothelial cells (26) . However, the concentrations of PPARD agonists in these experiments were above the specific PPARD activation range and PPARD downregulation or overexpression failed to alter the agonist's effects (25) , thus suggesting that non-PPARD-mediated mechanisms are involved. Other researchers have questioned whether PPARD affects TAK1 activity because PPARD downregulation via siRNA in HeLa cells reduced TAK1 phosphorylation, whereas PPARD overexpression in HEK293T cells failed to increase TAK1 phosphorylation (27) . In contrast with these ambiguous results, our data clearly show that PPARD increases TAK1 phosphorylation in both in vitro and in vivo PPARD gain-and loss-offunction models. Moreover, our results elucidate the mechanism by which PPARD regulates TAK1:
transcriptional upregulation of BMP7. BMP7, which is upregulated or amplified in 16% to 24% of human colorectal cancers in the TCGA databases ( Supplementary Fig. 5a ), negatively affects CRC patients' survival ( Fig. 5d ,e and Supplementary Fig. 5c ) and promotes colon cancer invasiveness (28) . TAK1
phosphorylation is being investigated clinically as a molecular target in the treatment of human cancers (29) . Our identification of PPARD, a druggable protein, as a regulator of the BMP7/TAK1 signaling pathway suggests a novel approach to therapeutically target BMP7/TAK1.
Our findings also provide important new insights regarding PPARD's effects on APC mutationdriven CRC tumorigenesis. Our novel mouse models of PPARD overexpression in IECs with APC mutations clearly show that PPARD strongly promotes CRC tumorigenesis. Prior studies were limited to PPARD KO modeling in APC-mutant mice. PPARD is, however, upregulated (6-9), not deleted, in human CRC ( Supplementary Fig. 5d ). Thus, we tested PPARD's effects not only in Apc min mice, which develop small intestinal adenomas, but also in Apc mutations better simulate human CRC. In contrast with the conflicting data from experiments with Apc min mice with germline PPARD KO, in all of our models, PPARD strongly potentiated APC mutationdriven CRC tumorigenesis. Other researchers have reported that PPARD activation with GW501516 significantly increased tumor numbers and sizes in the small intestines in Apc min mice (30) . Our data showed not only that GW501516 significantly increased intestinal tumorigenesis in large intestines of Apc Δ 580 mice but also, for the first time, that a PPARD inhibitor, GSK3787, had antitumorigenic activity in in vivo CRC models. APC mutations occur later in life in the majority of patients with CRC; fewer than 1% have germline APC mutations(31). Our novel Apc APC mutations alone are insufficient to induce CRC invasiveness (3, 32) . Our findings demonstrate the mechanistic significance of PPARD overexpression in IECs for CRC invasiveness. PPARD overexpression in intestinal cells significantly increased CRC invasiveness in both our early-and lateonset APC mutation mouse models. These novel findings are relevant to human CRC; using CRC patient samples, we found that PPARD was more strongly upregulated in CRC invasive fronts (an indicator of CRC invasiveness in humans (33, 34) ) than in paired adenomas or even invasive cancer centers.
Furthermore, functional proteomic analyses identified multiple pathways, including PDGFRβ, AKT1, CDK1, EIF4G, and connexin 43, that strongly promote CRC tumorigenesis and invasiveness.
PPARD upregulated connexin 43 in IECs in vivo, which is in agreement with our previously published data from differential transcriptome analyses of HCT-116 and KO1 cells (9) . Our results however demonstrate for the first time that PDGFRβ, a key gene in colorectal adenoma-to-carcinoma progression (35) , is upregulated by PPARD to promote CRC tumorigenesis. Our data, however, show for the first time that PPARD increases GSK3β phosphorylation to drive colorectal tumorigenesis.
Dysregulation of mRNA translation plays a very important role in tumorigenesis and cancer progression (43) . Tumorigenesis enhances aberrant mRNA translation via multiple mechanisms, including AKT/mTOR activating phosphorylation of S6K1/2 and inactivating phosphorylation of EIF4E-binding proteins to release EIF4E, which subsequently forms a protein complex with other eukaryotic translation initiation factors (e.g., EIF4G) and initiates mRNA translation (43) . Enhancement of the EIF4E-EIF4G interaction promotes the development of cancer-cell resistance to BRAF and MEK inhibitors (44) , and EIF4G overexpression in solid tumors promotes tumor progression (43) . Our novel finding that PPARD upregulated EIF4G expression in IECs is an additional mechanism by which PPARD promotes tumorigenesis and progression. We also demonstrated for the first time that PPARD upregulated CDK1 in IECs. CDK1 regulates cell cycle-dependent (e.g., chromosome segregation, DNA repair(45)) and -independent functions (e.g., promotion of protein translation independent of AKT (46)) to promote tumorigenesis and progression and therefore is considered a potential cancer therapeutic target (47) . In sum, these novel findings demonstrate PPARD's pleiotropic effects in IECs to enhance RNA translation and cancer invasiveness.
METHODS
Mouse models
Mouse care and experimental protocols were approved by and conducted in accordance with the guidelines of the Animal Care and Use Committee of The University of Texas MD Anderson Cancer
Center. We generated mice with targeted PPARD overexpression in IECs (PD mice) via a villin promoter as described previously (48 
Cell lines
The human colon cancer cell lines SW480 and SW620 and the mouse colon cancer cell line CT26 were Institute at MD Anderson Cancer Center, and its authenticity was confirmed by liquid chromatographymass spectrometry analyses using standard GSK3787 purchased from Sigma (Cat# G7423). were followed until they required euthanasia on the basis of 1 of the following preset criteria: (1) persistent rectal bleeding for 3 consecutive days or (2) weight loss of more than 20%.
Apc
Mouse intestinal tumorigenesis evaluation
The mice were euthanized, and their abdomens were opened. The intestines from the rectum to the base of the stomach were removed and washed with phosphate-buffered saline (PBS). For whole intestinal mount (Swiss roll) analyses, one end of the intestine was ligated, and the intestine was inflated with 10% neutral formalin to fix overnight. The formalin was replaced with 70% ethanol prior to paraffin embedding. Tumors were counted under a stereotype microscope (Nikon Eclipse TE2000). The intestines were rolled up using a paper clip with a small loop to make Swiss rolls. The rolls were tied off on both ends using a 25-gauge syringe needle, cut in half, and placed in a paraffin cassette for The tissue sections were cut for hematoxylin (Agilent Dako) and eosin (Fisher Scientific) staining, and then H&E-stained sections were scanned using an Aperio digital pathology slide scanner (Leica Biosystems) for taking photomicrographs and counting tumors. Classification and grading of H&E-stained sections, including scoring tumor invasiveness, were performed by an experienced pathologist using an Olympus BX41 microscope.
Primary organoid culture
Six-week-old PD mice and wild-type (WT) littermates (n = 6 mice per group) were killed, and their colons were harvested. Harvested colon tissues were digested with 10 mM ethylenediaminetetraacetic acid (Sigma) to the media for the first 2 days' culture, then changed the media without Y-27632 for later culture. The medium was replaced with fresh medium every 2 or 3 days. Organoids were maintained in an incubator with an atmosphere of 5% CO 2 . Organoids were counted, imaged, and quantified on day 7 of culture.
IHC and IF staining
Paraffin-embedded tissue sections 5 µm thick were deparaffinized and rehydrated, and antigen retrieval was performed with an antigen unmasking solution (Vector Laboratory). The samples were then incubated in blocking buffer (PBS with 1.5% goat serum and 0.3% Triton X-100) for 1 h at room temperature and incubated with primary antibodies in a humidified chamber at 4°C overnight. For IHC staining, the following primary antibodies were used: 
Generation of cell lines stably transfected with PPARD overexpression plasmid
The full length of the human PPARD cDNA was subcloned into a pcDNA3.1 plasmid (Life 
RNA extraction and quantitative real-time polymerase chain reaction
Mouse intestines were digested with 10 mM EDTA (pH 8.0) at room temperature for 10 min, and then digested crypts were harvested from the supernatants for further analysis. Total RNA was extracted from digested intestinal crypt cells from the mice or cancer cell lines using TRIzol for cell lines or an RNeasy Microarray Tissue Mini Kit (Qiagen) for tissue cells according to the manufacturer's protocol.
cDNA was synthesized using a Bio-Rad cDNA Synthesis Kit (Bio-Rad Laboratory). Quantitative realtime polymerase chain reaction (qRT-PCR) analyses were performed using a FastStart universal probe master (Roche) and StepOnePlus PCR system (Applied Biosystems). All the qRT-PCR probes were purchased from Applied Biosystems. See Table S2 for probe details. The relative RNA expression levels were normalized to the expression of mouse ACTB or human HPRT1 (Applied Biosystems), and calculated using a comparative threshold cycle method (ddC t ).
Western blotting analysis
Cells or digested intestinal crypts were homogenized in lysis buffer (0. Next, the blots were hybridized with the secondary antibody for 1 h at room temperature. The blots were analyzed using enhanced chemiluminescence (GE Healthcare).
Functional proteomics reverse phase protein array analysis
Reverse phase protein array (RPPA) analysis was performed on isolated intestinal epithelial cells from Apc for biological significance and Student's t-test P values (−log 10 [P value]) for statistical significance were used. We considered proteins as altered by PPARD overexpression if the absolute fold-change difference was greater than 2 or less than 0.5 and the Student's t-test P value was less than 0.05; volcano plots were constructed.
Chromatin immunoprecipitation-quantitative PCR assay
To determine whether PPARD binds to target gene (BMP7 or AKT1) promoters, we subjected SW480 
Statistical analyses
Quantifiable outcome measures for 1 factor in experimental conditions were compared using 1-way analysis of variance, and Bonferroni adjustments were used for all multiple comparisons. We used 2-
way analysis of variance to analyze data involving the simultaneous consideration of 2 factors. Tumor incidence was compared using chi-square tests. Survival rates as a function of time were estimated using the Kaplan-Meier method. The data were log-transformed as necessary to accommodate the normality and homoscedasticity assumptions implicit to the statistical procedures used. Data were analyzed using SAS software, version 9.4 (SAS Institute, Cary, NC) or GraphPad Prism 7.01. All tests were 2-sided and conducted at a significance level of P < 0.05.
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